BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 14, 2026; 32(14): 115790
Published online Apr 14, 2026. doi: 10.3748/wjg.v32.i14.115790
Table 4 Effect of protective agent uses on significant hemoglobin drop incidences for aspirin or clopidogrel alone users in self-controlled case series analyses
Exposure period
Aspirin-alone users (n = 351)
Clopidogrel-alone users (n = 35)
Concurrent users of aspirin & clopidogrel (n = 30)
Concomitant users of aspirin & clopidogrel (n = 348)
IRR (95%CI)
P value
IRR (95%CI)
P value
IRR (95%CI)
P value
IRR (95%CI)
P value
All SHD events
    Mucosal DA aloneReferenceReference
    PPI0.33 (0.21-0.52)< 0.0010.43 (0.09-2.13)0.3010.39 (0.10-1.60)0.1910.43 (0.30-0.62)< 0.001
    PPI & rebamipide0.35 (0.06-1.90)0.223
    PPI & H2RA0.54 (0.18-1.64)0.281
    PPI & others0.14 (0.02-1.02)0.052
    Rebamipide0.69 (0.36-1.34)0.2760.25 (0.02-2.87)0.2631.49 (0.87-2.57)0.148
    Rebamipide & H2RA0.61 (0.12-3.17)0.5530.27 (0.05-1.35)0.111
    H2RA0.60 (0.43-0.83)0.0021.85 (0.55-6.23)0.3221.02 (0.42-2.53)0.9580.93 (0.67-1.29)0.661
    H2RA & others0.46 (0.07-2.95)0.411
    Others0.47 (0.20-1.10)0.0812.34 (0.32-17.19)0.4030.40 (0.15-1.07)0.068
First SHD event only
    Mucosal DA aloneReferenceReference
    PPI0.33 (0.21-0.51)< 0.0010.42 (0.08-2.08)0.2860.39 (0.10-1.60)0.1910.45 (0.31-0.65)< 0.001
    PPI & rebamipide0.35 (0.06-1.91)0.224
    PPI & H2RA0.81 (0.26-2.50)0.708
    PPI & others0.15 (0.02-1.04)0.055
    Rebamipide0.74 (0.38-1.44)0.3800.26 (0.02-3.07)0.2851.46 (0.85-2.52)0.173
    Rebamipide & H2RA0.60 (0.12-3.15)0.549
    H2RA0.62 (0.44-0.86)< 0.0012.22 (0.59-8.33)0.2391.02 (0.42-2.53)0.9580.96 (0.69-1.34)0.814
    H2RA & others0.45 (0.07-2.89)0.401
    Others0.48 (0.20-1.12)0.0902.30 (0.31-16.93)0.413


Write to the Help Desk